Document is current

Any future updates will be listed below

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells

Crossref DOI link: https://doi.org/10.1186/s12974-015-0365-x

Published Online: 2015-08-12

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark